DrugsNews.net

Drugs Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Farmaexplorer.it

Relyvrio, a new treatment option for patients with amyotrophic lateral sclerosis, FDA approved


The U.S. Food and Drug Administration ( FDA ) has approved Relyvrio ( Sodium Phenylbutyrate / Taurursodiol ) to treat patients with amyotrophic lateral sclerosis ( ALS ), commonly referred to as Lou Gehrig’s disease.

Amyotrophic lateral sclerosis is a rare disease that attacks and kills the nerve cells that control voluntary muscles. Voluntary muscles produce movements such as chewing, walking, breathing, and talking.
Amyotrophic lateral sclerosis causes the nerves to lose the ability to activate specific muscles, which causes the muscles to become weak and leads to paralysis. ALS is a progressive disease that continues to get worse over time. Most cases will result in death from respiratory failure, usually within three to five years from when the symptoms first appear.
Approximately 5,000 individuals in the United States are diagnosed with amyotrophic lateral sclerosis annually, and approximately 20,000 Americans are currently living with the disease.

Relyvrio can be taken orally by combining one packet in 8 ounces of room temperature water. It can also be administered through a feeding tube.
The recommended dosage for the first three weeks is one packet ( 3 grams Sodium Phenylbutyrate and 1-gram Taurursodiol ) daily. After three weeks, the dosage increases to one packet twice a day. The medication can be taken before a snack or meal.

The efficacy of Relyvrio for the treatment of amyotrophic lateral sclerosis was demonstrated in a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
In the trial, 137 adult patients with amyotrophic lateral sclerosis were randomized to receive either Relyvrio or placebo.
The patients treated with Relyvrio experienced a slower rate of decline on a clinical assessment of daily functioning compared to those receiving a placebo.
Additionally, longer overall survival was observed in a post hoc, long-term analysis of patients who originally received Relyvrio versus those who originally received placebo.

The most common adverse reactions experienced with Relyvrio were diarrhea, abdominal pain, nausea and upper respiratory tract infection.
Relyvrio contains Taurursodiol, a bile acid, which may cause worsening diarrhea in patients with disorders that interfere with bile acid circulation. These patients should consider consulting with a specialist before taking Relyvrio.

The FDA granted this application Priority Review designation. It also received orphan drug designation. ( Xagena )

Source: FDA, 2022

XagenaMedicine_2022



Indietro